The Efficacy of Harpagophytum procumbens (Teltonal) in Patients with Knee Osteoarthritis: A Randomized Active-Controlled Clinical Trial
Purpose. The high prevalence of knee osteoarthritis (KOA) is a major cause of disability among elders. NSAIDs are recommended to reduce KOA patients’ symptoms, but their adverse side effects limit their consumption. In this study, we evaluated the effectiveness of Harpagophytum procumbens compared t...
Gespeichert in:
| Veröffentlicht in: | Evidence-based complementary and alternative medicine 2021, Vol.2021, p.5596892-8 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8 |
|---|---|
| container_issue | |
| container_start_page | 5596892 |
| container_title | Evidence-based complementary and alternative medicine |
| container_volume | 2021 |
| creator | Farpour, Hamid Reza Rajabi, Najme Ebrahimi, Bahareh |
| description | Purpose. The high prevalence of knee osteoarthritis (KOA) is a major cause of disability among elders. NSAIDs are recommended to reduce KOA patients’ symptoms, but their adverse side effects limit their consumption. In this study, we evaluated the effectiveness of Harpagophytum procumbens compared to a routine NSAID (meloxicam) on pain reduction and functional improvement of KOA patients. Patients and Methods. Sixty patients aged 40–60 years, with painful knee osteoarthritis (grades 1-2 of Kellgren–Lawrence scale) for at least one month, were randomized into two groups with different routine medication periods. Group A consisted of daily administration of two Harpagophytum procumbens (Teltonal) tablets (2∗480 mg) for one month, and group B consisted of daily administration of meloxicam (15 mg) for ten days. The visual analogue scale (VAS), Western Ontario McMaster University Osteoarthritis Index (WOMAC), Oxford Knee Scale (OKS), and patient satisfaction were evaluated at the baseline and after 2, 4, and 8 weeks. Results. There were no statistically significant differences between demographic characteristics, pain intensity, and function scores before the treatment. VAS, OKS, and WOMAC scores improved in both groups p |
| doi_str_mv | 10.1155/2021/5596892 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8548091</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2590105781</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3632-4b9cd00bd64ef6f9f0411718db1a485b608013e54d681e041fecc989fce8a5e23</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEoqVw44wscSmCUDtxEpsD0mpVKKJSEVokbpbjjBtXjp3aTqvlD_C3SbTLCjhwmtHMo3c-3ix7TvBbQqrqrMAFOasqXjNePMiOSUNJTgvGHh7y5vtR9iTGG4wL3jTN4-yopA0pSloeZz83PaBzrY2Saou8RhcyjPLaj_02TQMag1fT0IKL6HQDNnkn7StkHPoikwGXIro3qUefHQC6igm8DKkPJpn4Dq3QV-k6P5gf0KGVSuYO8rV3KXhr58raGjdPtWgTjLRPs0da2gjP9vEk-_bhfLO-yC-vPn5ary5zVdZlkdOWqw7jtqsp6FpzjSkhDWFdSyRlVVtjhkkJFe1qRmBualCKM64VMFlBUZ5k73e649QO0Kn5hiCtGIMZZNgKL434u-NML679nWAVZZiTWeB0LxD87QQxicFEBdZKB36Koqg4Jrhq2IK-_Ae98VOYP7hQjNcLtmz0Zkep4GMMoA_LECwWh8XisNg7POMv_jzgAP-2dAZe74DeuE7em__L_QJzFq-1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2589610572</pqid></control><display><type>article</type><title>The Efficacy of Harpagophytum procumbens (Teltonal) in Patients with Knee Osteoarthritis: A Randomized Active-Controlled Clinical Trial</title><source>Wiley Online Library Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Farpour, Hamid Reza ; Rajabi, Najme ; Ebrahimi, Bahareh</creator><contributor>Xing, Guoqiang ; Guoqiang Xing</contributor><creatorcontrib>Farpour, Hamid Reza ; Rajabi, Najme ; Ebrahimi, Bahareh ; Xing, Guoqiang ; Guoqiang Xing</creatorcontrib><description>Purpose. The high prevalence of knee osteoarthritis (KOA) is a major cause of disability among elders. NSAIDs are recommended to reduce KOA patients’ symptoms, but their adverse side effects limit their consumption. In this study, we evaluated the effectiveness of Harpagophytum procumbens compared to a routine NSAID (meloxicam) on pain reduction and functional improvement of KOA patients. Patients and Methods. Sixty patients aged 40–60 years, with painful knee osteoarthritis (grades 1-2 of Kellgren–Lawrence scale) for at least one month, were randomized into two groups with different routine medication periods. Group A consisted of daily administration of two Harpagophytum procumbens (Teltonal) tablets (2∗480 mg) for one month, and group B consisted of daily administration of meloxicam (15 mg) for ten days. The visual analogue scale (VAS), Western Ontario McMaster University Osteoarthritis Index (WOMAC), Oxford Knee Scale (OKS), and patient satisfaction were evaluated at the baseline and after 2, 4, and 8 weeks. Results. There were no statistically significant differences between demographic characteristics, pain intensity, and function scores before the treatment. VAS, OKS, and WOMAC scores improved in both groups p<0.001 over time, but no significant superiority was shown; after 8 weeks: VAS (Teltonal (4.80 ± 1.80) vs. meloxicam (5.06 ± 1.43)), OKS (34.06 ± 4.38, 34.00 ± 7.87, Teltonal vs. meloxicam, respectively), and WOMAC scores (25.73 ± 10.11 Teltonal vs. 26.20 ± 13.94, meloxicam). Conclusion. Teltonal is an effective and safe treatment in patients with mild KOA in the short term. However, no significant superiority was shown in using Teltonal or meloxicam, in people who cannot take NSAIDs, it can be a good alternative, although difference in medication periods should be considered.</description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2021/5596892</identifier><identifier>PMID: 34712343</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Analgesics ; Anti-inflammatory agents ; Anticoagulants ; Back pain ; Body mass index ; Clinical trials ; Disease ; Evidence-based medicine ; Gene expression ; Harpagophytum procumbens ; Knee ; Meloxicam ; Nonsteroidal anti-inflammatory drugs ; Older people ; Osteoarthritis ; Pain ; Patient satisfaction ; Patients ; Rheumatoid arthritis ; Statistical analysis ; Variance analysis</subject><ispartof>Evidence-based complementary and alternative medicine, 2021, Vol.2021, p.5596892-8</ispartof><rights>Copyright © 2021 Hamid Reza Farpour et al.</rights><rights>Copyright © 2021 Hamid Reza Farpour et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2021 Hamid Reza Farpour et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3632-4b9cd00bd64ef6f9f0411718db1a485b608013e54d681e041fecc989fce8a5e23</citedby><cites>FETCH-LOGICAL-c3632-4b9cd00bd64ef6f9f0411718db1a485b608013e54d681e041fecc989fce8a5e23</cites><orcidid>0000-0001-8959-8202</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548091/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548091/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4010,27902,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34712343$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Xing, Guoqiang</contributor><contributor>Guoqiang Xing</contributor><creatorcontrib>Farpour, Hamid Reza</creatorcontrib><creatorcontrib>Rajabi, Najme</creatorcontrib><creatorcontrib>Ebrahimi, Bahareh</creatorcontrib><title>The Efficacy of Harpagophytum procumbens (Teltonal) in Patients with Knee Osteoarthritis: A Randomized Active-Controlled Clinical Trial</title><title>Evidence-based complementary and alternative medicine</title><addtitle>Evid Based Complement Alternat Med</addtitle><description>Purpose. The high prevalence of knee osteoarthritis (KOA) is a major cause of disability among elders. NSAIDs are recommended to reduce KOA patients’ symptoms, but their adverse side effects limit their consumption. In this study, we evaluated the effectiveness of Harpagophytum procumbens compared to a routine NSAID (meloxicam) on pain reduction and functional improvement of KOA patients. Patients and Methods. Sixty patients aged 40–60 years, with painful knee osteoarthritis (grades 1-2 of Kellgren–Lawrence scale) for at least one month, were randomized into two groups with different routine medication periods. Group A consisted of daily administration of two Harpagophytum procumbens (Teltonal) tablets (2∗480 mg) for one month, and group B consisted of daily administration of meloxicam (15 mg) for ten days. The visual analogue scale (VAS), Western Ontario McMaster University Osteoarthritis Index (WOMAC), Oxford Knee Scale (OKS), and patient satisfaction were evaluated at the baseline and after 2, 4, and 8 weeks. Results. There were no statistically significant differences between demographic characteristics, pain intensity, and function scores before the treatment. VAS, OKS, and WOMAC scores improved in both groups p<0.001 over time, but no significant superiority was shown; after 8 weeks: VAS (Teltonal (4.80 ± 1.80) vs. meloxicam (5.06 ± 1.43)), OKS (34.06 ± 4.38, 34.00 ± 7.87, Teltonal vs. meloxicam, respectively), and WOMAC scores (25.73 ± 10.11 Teltonal vs. 26.20 ± 13.94, meloxicam). Conclusion. Teltonal is an effective and safe treatment in patients with mild KOA in the short term. However, no significant superiority was shown in using Teltonal or meloxicam, in people who cannot take NSAIDs, it can be a good alternative, although difference in medication periods should be considered.</description><subject>Analgesics</subject><subject>Anti-inflammatory agents</subject><subject>Anticoagulants</subject><subject>Back pain</subject><subject>Body mass index</subject><subject>Clinical trials</subject><subject>Disease</subject><subject>Evidence-based medicine</subject><subject>Gene expression</subject><subject>Harpagophytum procumbens</subject><subject>Knee</subject><subject>Meloxicam</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Older people</subject><subject>Osteoarthritis</subject><subject>Pain</subject><subject>Patient satisfaction</subject><subject>Patients</subject><subject>Rheumatoid arthritis</subject><subject>Statistical analysis</subject><subject>Variance analysis</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kU1v1DAQhiMEoqVw44wscSmCUDtxEpsD0mpVKKJSEVokbpbjjBtXjp3aTqvlD_C3SbTLCjhwmtHMo3c-3ix7TvBbQqrqrMAFOasqXjNePMiOSUNJTgvGHh7y5vtR9iTGG4wL3jTN4-yopA0pSloeZz83PaBzrY2Saou8RhcyjPLaj_02TQMag1fT0IKL6HQDNnkn7StkHPoikwGXIro3qUefHQC6igm8DKkPJpn4Dq3QV-k6P5gf0KGVSuYO8rV3KXhr58raGjdPtWgTjLRPs0da2gjP9vEk-_bhfLO-yC-vPn5ary5zVdZlkdOWqw7jtqsp6FpzjSkhDWFdSyRlVVtjhkkJFe1qRmBualCKM64VMFlBUZ5k73e649QO0Kn5hiCtGIMZZNgKL434u-NML679nWAVZZiTWeB0LxD87QQxicFEBdZKB36Koqg4Jrhq2IK-_Ae98VOYP7hQjNcLtmz0Zkep4GMMoA_LECwWh8XisNg7POMv_jzgAP-2dAZe74DeuE7em__L_QJzFq-1</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Farpour, Hamid Reza</creator><creator>Rajabi, Najme</creator><creator>Ebrahimi, Bahareh</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8959-8202</orcidid></search><sort><creationdate>2021</creationdate><title>The Efficacy of Harpagophytum procumbens (Teltonal) in Patients with Knee Osteoarthritis: A Randomized Active-Controlled Clinical Trial</title><author>Farpour, Hamid Reza ; Rajabi, Najme ; Ebrahimi, Bahareh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3632-4b9cd00bd64ef6f9f0411718db1a485b608013e54d681e041fecc989fce8a5e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analgesics</topic><topic>Anti-inflammatory agents</topic><topic>Anticoagulants</topic><topic>Back pain</topic><topic>Body mass index</topic><topic>Clinical trials</topic><topic>Disease</topic><topic>Evidence-based medicine</topic><topic>Gene expression</topic><topic>Harpagophytum procumbens</topic><topic>Knee</topic><topic>Meloxicam</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Older people</topic><topic>Osteoarthritis</topic><topic>Pain</topic><topic>Patient satisfaction</topic><topic>Patients</topic><topic>Rheumatoid arthritis</topic><topic>Statistical analysis</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farpour, Hamid Reza</creatorcontrib><creatorcontrib>Rajabi, Najme</creatorcontrib><creatorcontrib>Ebrahimi, Bahareh</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farpour, Hamid Reza</au><au>Rajabi, Najme</au><au>Ebrahimi, Bahareh</au><au>Xing, Guoqiang</au><au>Guoqiang Xing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Efficacy of Harpagophytum procumbens (Teltonal) in Patients with Knee Osteoarthritis: A Randomized Active-Controlled Clinical Trial</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><addtitle>Evid Based Complement Alternat Med</addtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><spage>5596892</spage><epage>8</epage><pages>5596892-8</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract>Purpose. The high prevalence of knee osteoarthritis (KOA) is a major cause of disability among elders. NSAIDs are recommended to reduce KOA patients’ symptoms, but their adverse side effects limit their consumption. In this study, we evaluated the effectiveness of Harpagophytum procumbens compared to a routine NSAID (meloxicam) on pain reduction and functional improvement of KOA patients. Patients and Methods. Sixty patients aged 40–60 years, with painful knee osteoarthritis (grades 1-2 of Kellgren–Lawrence scale) for at least one month, were randomized into two groups with different routine medication periods. Group A consisted of daily administration of two Harpagophytum procumbens (Teltonal) tablets (2∗480 mg) for one month, and group B consisted of daily administration of meloxicam (15 mg) for ten days. The visual analogue scale (VAS), Western Ontario McMaster University Osteoarthritis Index (WOMAC), Oxford Knee Scale (OKS), and patient satisfaction were evaluated at the baseline and after 2, 4, and 8 weeks. Results. There were no statistically significant differences between demographic characteristics, pain intensity, and function scores before the treatment. VAS, OKS, and WOMAC scores improved in both groups p<0.001 over time, but no significant superiority was shown; after 8 weeks: VAS (Teltonal (4.80 ± 1.80) vs. meloxicam (5.06 ± 1.43)), OKS (34.06 ± 4.38, 34.00 ± 7.87, Teltonal vs. meloxicam, respectively), and WOMAC scores (25.73 ± 10.11 Teltonal vs. 26.20 ± 13.94, meloxicam). Conclusion. Teltonal is an effective and safe treatment in patients with mild KOA in the short term. However, no significant superiority was shown in using Teltonal or meloxicam, in people who cannot take NSAIDs, it can be a good alternative, although difference in medication periods should be considered.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>34712343</pmid><doi>10.1155/2021/5596892</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8959-8202</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1741-427X |
| ispartof | Evidence-based complementary and alternative medicine, 2021, Vol.2021, p.5596892-8 |
| issn | 1741-427X 1741-4288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8548091 |
| source | Wiley Online Library Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Analgesics Anti-inflammatory agents Anticoagulants Back pain Body mass index Clinical trials Disease Evidence-based medicine Gene expression Harpagophytum procumbens Knee Meloxicam Nonsteroidal anti-inflammatory drugs Older people Osteoarthritis Pain Patient satisfaction Patients Rheumatoid arthritis Statistical analysis Variance analysis |
| title | The Efficacy of Harpagophytum procumbens (Teltonal) in Patients with Knee Osteoarthritis: A Randomized Active-Controlled Clinical Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A25%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Efficacy%20of%20Harpagophytum%20procumbens%20(Teltonal)%20in%20Patients%20with%20Knee%20Osteoarthritis:%20A%20Randomized%20Active-Controlled%20Clinical%20Trial&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=Farpour,%20Hamid%20Reza&rft.date=2021&rft.volume=2021&rft.spage=5596892&rft.epage=8&rft.pages=5596892-8&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2021/5596892&rft_dat=%3Cproquest_pubme%3E2590105781%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2589610572&rft_id=info:pmid/34712343&rfr_iscdi=true |